Fig. 3From: Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugationSDS PAGE analysis of 4D5scFv-HSA conjugation mixtures (S122; 4D5scFv-S122-HSA, G125; 4D5scFv-G125-HSA, S127; 4D5scFv-S127-HSA, P177; 4D5scFv-P177-HSA and G178; 4D5scFv-G178-HSA). Coomassie-stained protein gels of 4D5scFv variants incubated in the presence (+) or absence (-) of TCO-HSABack to article page